LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study.
OBJECTIVE
To investigate the relationship between coronary artery remodelling and glycaemic and lipid profiles in diabetic patients.


RESULTS
Intravascular ultrasound analyses of 131 angiographically non-significant coronary stenoses in 80 diabetic patients were performed. The remodelling index (RI) was calculated as the ratio between total vessel area at target site and total vessel area at proximal reference, and was assessed in two ways: as a continuous variable, and as a binary categorical variable: RI<1 namely, negative remodelling (group I), or RI> or =1 (group II). Percentage cross-sectional narrowing was 57+/-13%. On average, RI was 0.93+/-0.13. Coronary shrinkage was found in 94 (71.7%) lesions. Significant inverse correlations were demonstrated between RI and total cholesterol (r=-0.26, P=0.003), apolipoprotein-B (r=-0.23, P=0.01) and LDL-cholesterol (r=-0.3, P=0.001) levels. Multivariable lineal regression analysis identified LDL-cholesterol as the only independent predictor of RI (P=0.001).


CONCLUSIONS
Negative remodelling is a frequent finding in diabetics and it is associated with LDL-cholesterol levels. This may contribute to the diffuse coronary artery disease observed in diabetic patients.
Jiménez-Quevedo
Pilar
P
Interventional Cardiology Unit, Cardiovascular Institute, Hospital Clínico San Carlos, C/Prof. Martín Lagos s/n, 28040 Madrid, Spain.
Sabaté
Manel
M
Angiolillo
Dominick
D
Alfonso
Fernando
F
Hernández-Antolín
Rosana
R
Bañuelos
Camino
C
Bernardo
Esther
E
Ramirez
Celia
C
Moreno
Raúl
R
Fernández
Cristina
C
Escaned
Javier
J
Macaya
Carlos
C
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood*; D023921:Coronary Stenosis / Q000097:blood* / Q000000981:diagnostic imaging / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology*; D003925:Diabetic Angiopathies / Q000097:blood* / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007333:Insulin Resistance; D008297:Male; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D014463:Ultrasonography
D001786:Blood Glucose; D008078:Cholesterol, LDL; D007166:Immunosuppressive Agents; D020123:Sirolimus